Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-muscle Invasive Bladder Cancer: early-phase trial registry
16 of 31 indexed Non-muscle Invasive Bladder Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 16 currently recruiting · #495 of 28,707 conditions by registered trial count
Non-muscle Invasive Bladder Cancer: 31 US clinical trials tracked, 16 recruiting.
Non-muscle Invasive Bladder Cancer is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition non-muscle-invasive-bladder-cancer
OPEN 16 | RECR 52% | LATE 6 | EARLY 18 | RANK #495 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Cutaneous Melanoma (52% recruiting · 31 trials)
Non-muscle Invasive Bladder Cancer lists 16 open slots (52% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-muscle Invasive Bladder Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-muscle Invasive Bladder Cancer is recruiting above its size-band peers.
16 of 31 indexed trials (51.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-muscle Invasive Bladder Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 3 of 31 trials (9.7%). 25 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-muscle Invasive Bladder Cancer enrolment sits around 116 participants.
Median target enrolment is 116 among the 31 trials that report a genuine target (sentinel values excluded). 14 of those (45.2%) plan for fewer than 100 participants.
-
Non-muscle Invasive Bladder Cancer research is mostly interventional.
25 interventional and 6 observational studies make up this index (80.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
University of Texas Southwestern Medical Center
NCT05825950
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
ImmunityBio
NCT02138734
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Pfizer
NCT07206225
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
White River Junction Veterans Affairs Medical Center
NCT05796375
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Robert Svatek
NCT04375813
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
ImmVira Pharma Co.
NCT06971614
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Protara Therapeutics
NCT05951179
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
NCT06929286
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
SURGE Therapeutics
NCT05710848
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
John Sfakianos
NCT06503614
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Memorial Sloan Kettering Cancer Center
NCT05126472
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
NCT05483868
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Johns Hopkins University
NCT05672615
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Merck Sharp & Dohme
NCT06637423
Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
University of Virginia
NCT05790850
A Phase I Intravesical PPM Therapy for NMIBC
VA Office of Research and Development
NCT05519241
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Pfizer
NCT04165317
Intravesical BCG vs GEMDOCE in NMIBC
ECOG-ACRIN Cancer Research Group
NCT05538663
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
University of Washington
NCT03933826
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology
NCT06111235
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Tyra Biosciences
NCT05544552
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
CG Oncology
NCT04452591
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
AstraZeneca
NCT05943106
A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
Prokarium
NCT06181266
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
H. Lee Moffitt Cancer Center and Research Institute
NCT06253845
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
ImmunityBio
NCT05981131
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
Genomic Health®
NCT02969109
Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT00582387
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03914794
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology
NCT03081858
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
Protara Therapeutics
NCT05085977
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 6 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-muscle Invasive Bladder Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-muscle Invasive Bladder Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-muscle Invasive Bladder Cancer page
31 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Non-muscle Invasive Bladder Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Non-muscle Invasive Bladder Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-muscle Invasive Bladder Cancer condition card totals 31 registered trials; most-linked intervention n-dodecyl-B-D-maltoside; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.